Three newly approved drugs for chronic lymphocytic leukemia: Incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 7, 2015, Pages 385-391

  Sanford, David S ^a   Wierda, William G ^a   Burger, Jan A ^a   Keating, Michael J ^a   O'Brien, Susan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti CD20 antibody; BTK inhibitor; Lymphoid malignancy; Novel agents; PI3K inhibitor

Indexed keywords

IBRUTINIB; IDELALISIB; OBINUTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RISK; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; FOLLOW UP; HUMAN; LEUKEMIA RELAPSE; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PURINES; PYRAZOLES; PYRIMIDINES; QUINAZOLINONES;

EID: 84937514315     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2015.02.019     Document Type: Review

References (55)

1. M. Duhren-von Minden, R. Ubelhart, D. Schneider, and et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling Nature 489 2012 309 312
2. J.C. Byrd, R.R. Furman, S.E. Coutre, and et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia N Engl J Med 369 2013 32 42
3. S. O'Brien, R.R. Furman, S.E. Coutre, and et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial Lancet Oncol 15 2014 48 58
4. J.C. Byrd, J.R. Brown, S. O'Brien, and et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia N Engl J Med 371 2014 213 223
5. J.R. Brown, J.C. Byrd, S.E. Coutre, and et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia Blood 123 2014 3390 3397
6. R.R. Furman, J.P. Sharman, S.E. Coutre, and et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia N Engl J Med 370 2014 997 1007
7. G. Cartron, S. de Guibert, M.S. Dilhuydy, and et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study Blood 124 2014 2196 2202
8. V. Goede, K. Fischer, R. Busch, and et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions N Engl J Med 370 2014 1101 1110
9. A.M. Avalos, F. Meyer-Wentrup, and H.L. Ploegh B-cell receptor signaling in lymphoid malignancies and autoimmunity Adv Immunol 123 2014 1 49
10. K. Okkenhaug, A. Bilancio, G. Farjot, and et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice Science 297 2002 1031 1034
11. E. Clayton, G. Bardi, S.E. Bell, and et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation J Exp Med 196 2002 753 763
12. S.T. Jou, N. Carpino, Y. Takahashi, and et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex Mol Cell Biol 22 2002 8580 8591
13. M. Cully, H. You, A.J. Levine, and et al. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis Nat Rev Cancer 6 2006 184 192
14. Z.J. Zou, R. Zhang, L. Fan, and et al. Low expression level of phosphatase and tensin homolog deleted on chromosome ten predicts poor prognosis in chronic lymphocytic leukemia Leuk Lymphoma 54 2013 1159 1164
15. M. Barragan, B. Bellosillo, C. Campas, and et al. Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells Blood 99 2002 2969 2976
16. I. Ringshausen, F. Schneller, C. Bogner, and et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta Blood 100 2002 3741 3748
17. J. Hoellenriegel, S.A. Meadows, M. Sivina, and et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia Blood 118 2011 3603 3612
18. B.J. Lannutti, S.A. Meadows, S.E. Herman, and et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Blood 117 2011 591 594
19. J. Valiaho, C.I. Smith, and M. Vihinen BTKbase: the mutation database for X-linked agammaglobulinemia Hum Mutat 27 2006 1209 1217
20. L. Wang, M.S. Lawrence, Y. Wan, and et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia N Engl J Med 365 2011 2497 2506
21. X.S. Puente, M. Pinyol, V. Quesada, and et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia Nature 475 2011 101 105
22. S.E. Herman, A.L. Gordon, E. Hertlein, and et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 Blood 117 2011 6287 6296
23. L.A. Honigberg, A.M. Smith, M. Sirisawad, and et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proc Natl Acad Sci U S A 107 2010 13075 13080
24. S. Cheng, J. Ma, A. Guo, and et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity Leukemia 28 2014 649 657
25. B.Y. Chang, M. Francesco, M.F. De Rooij, and et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients Blood 122 2013 2412 2424
26. R.H. Advani, J.J. Buggy, J.P. Sharman, and et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies J Clin Oncol 31 2013 88 94
27. M. Hallek, B.D. Cheson, D. Catovsky, and et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Blood 111 2008 5446 5456
28. Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia, Published online August 20, 2014; doi: 10.1038/leu.2014.247.
29. J.A. Woyach, R.R. Furman, T.M. Liu, and et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib N Engl J Med 370 2014 2286 2294
30. W.G. Wierda, T.J. Kipps, J. Mayer, and et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia J Clin Oncol 28 2010 1749 1755
31. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-Hodgkin Lymphomas version 4.2104. Available at: http://www.nccn.org/about/nhl.pdf. Accessed: August 20, 2014.
32. T.W. Kuijpers, R.J. Bende, P.A. Baars, and et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses J Clin Invest 120 2010 214 222
33. S.A. Beers, C.H. Chan, R.R. French, and et al. CD20 as a target for therapeutic type I and II monoclonal antibodies Semin Hematol 47 2010 107 114
34. D.G. Maloney Anti-CD20 antibody therapy for B-cell lymphomas N Engl J Med 366 2012 2008 2016
35. E. Mossner, P. Brunker, S. Moser, and et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity Blood 115 2010 4393 4402
36. W. Alduaij, A. Ivanov, J. Honeychurch, and et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies Blood 117 2011 4519 4529
37. L.H. Sehn, S.E. Assouline, D.A. Stewart, and et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies Blood 119 2012 5118 5125
38. G. Salles, F. Morschhauser, T. Lamy, and et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients Blood 119 2012 5126 5132
39. M. Hallek, K. Fischer, G. Fingerle-Rowson, and et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial Lancet 376 2010 1164 1174
40. C.S. Tam, S. O'Brien, W. Wierda, and et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia Blood 112 2008 975 980
41. A.M. Fink, S. Böttcher, M. Ritgen, and et al. Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab Leukemia 27 2013 1949 1952
42. ClinicalTrials.gov [Web site]. Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Available at: https://clinicaltrials.gov/ct2/show/NCT02048813. Accessed: September 8, 2014.
43. K. Fischer, P. Cramer, R. Busch, and et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group J Clin Oncol 29 2011 3559 3566
44. T. Robak, A. Dmoszynska, P. Solal-Celigny, and et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia J Clin Oncol 28 2010 1756 1765
45. W. Wierda, S. O'Brien, S. Wen, and et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia J Clin Oncol 23 2005 4070 4078
46. O'Brien SM, Furman R, Coutre SE, et al. Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease (abstract 7014). Presented at the 2014 ASCO Annual Meeting. Chicago, IL, May 30-June 3, 2014.
47. Brown JR, Hillmen P, O'Brien SM, et al. Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATE trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (abstract 3331). Presented at the 56th ASH Annual Meeting. San Francisco, CA, Deceber 6-9, 2014.
48. M. Hallek, N.E. Kay, A. Osterborg, and et al. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia Future Oncol 11 2015 51 59
49. ClinicalTrials.gov [Web site]. A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (NCT01569295). Available at: https://clinicaltrials.gov/ct2/show/NCT01569295. Accessed: October 28, 2014.
50. P. Dreger, P. Corradini, E. Kimby, and et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus Leukemia 21 2007 12 17
51. L. Sellner, S. Denzinger, S. Dietrich, and et al. What do we do with chronic lymphocytic leukemia with 17p deletion? Curr Hematol Malig Rep 8 2013 81 90
52. Poon ML, Fox PS, Samuels BI, et al. Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis. Leuk Lymphoma, Published online August 4, 2014, http://dx.doi.org/10.3109/10428194.2014.930848.
53. P. Dreger, H. Dohner, M. Ritgen, and et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial Blood 116 2010 2438 2447
54. O'Brien S, Jones JA, Coutre S, et al. Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE-17 Trial (abstract 327). Presented at the 56th ASH Annual Meeting, San Francisco, CA, December 6-9, 2014.
55. Red Book. Truven Health Analytics. Comprehensive, Consistent Drug Pricing Resource. Available at: http://sites.truvenhealth.com/redbook/index.html. Accessed: November 14, 2014.